

Disclosure continued.

Armstrong has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, EPI Health, Incyte, Janssen, Leo Pharma, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.

Lebwohl has received research funds on behalf of Mount Sinai from Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Aikium, Almirall, AltruBio Inc., Amgen, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Goodrx-Mayne, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sun Pharma, Takeda, Trevi, and Verrica.

Stein Gold has served as a consultant, advisory board member, and/or speaker for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Galderma, Incyte, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB.

Feldman has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena Pharmaceuticals, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Dermavant, Eurofins, Forte Biosciences, Galderma, GSK/Stiefel, Helsinn, Informa, Janssen, Leo Pharma, Lilly, Menlo, Merck, Mylan, National Biological Corporation, National Psoriasis Foundation, Novan, Novartis, Ortho Dermatologics, Pfizer, Qurient Therapeutics, Regeneron, Samsung, Sanofi, Sun Pharma, Teladoc, UCB, UpToDate, and vTv Therapeutics; is the founder and part owner of Causa Research; and is a shareholder of Sensal Health.

Thaçi has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Johnson & Johnson, Leo Pharma, Lilly, New Bridge, Novartis, Pfizer, Regeneron, Sanofi, Stada, Target RWE, UCB, and Vichy.